Table of Contents
International Scholarly Research Notices
Volume 2015 (2015), Article ID 480418, 6 pages
http://dx.doi.org/10.1155/2015/480418
Research Article

Association between Serum Bilirubin and Estimated Glomerular Filtration Rate among Diabetic Patients

1Department of Community Medicine, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan
2Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan

Received 27 October 2014; Revised 19 December 2014; Accepted 2 January 2015

Academic Editor: Hamadi Fetoui

Copyright © 2015 Takeaki Katoh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Tiribelli and J. D. Ostrow, “The molecular basis of bilirubin encephalopathy and toxicity: report of an EASL Single Topic Conference, Trieste, Italy, 1-2 October, 2004,” Journal of Hepatology, vol. 43, no. 1, pp. 156–166, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Novotný and L. Vítek, “Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies,” Experimental Biology and Medicine, vol. 228, no. 5, pp. 568–571, 2003. View at Google Scholar · View at Scopus
  3. J. Neuzil and R. Stocker, “Bilirubin attenuates radical-mediated damage to serum albumin,” FEBS Letters, vol. 331, no. 3, pp. 281–284, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Neuzil and R. Stocker, “Free and albumin-bound bilirubin are efficient co-antioxidants for α-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation,” Journal of Biological Chemistry, vol. 269, no. 24, pp. 16712–16719, 1994. View at Google Scholar · View at Scopus
  5. K. Ohnaka and S. Kono, “Bilirubin, cardiovascular diseases and cancer: epidemiological perspectives,” Expert Review of Endocrinology and Metabolism, vol. 5, no. 6, pp. 891–904, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Fukui, M. Tanaka, E. Shiraishi et al., “Relationship between serum bilirubin and albuminuria in patients with type 2 diabetes,” Kidney International, vol. 74, no. 9, pp. 1197–1201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. H. S. Shin, Y. S. Jung, and H. Rim, “Relationship of serum bilirubin concentration to kidney function and 24-hour urine protein in Korean adults,” BMC Nephrology, vol. 12, article 29, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Tanaka, M. Fukui, H. Okada et al., “Low serum bilirubin concentration is a predictor of chronic kidney disease,” Atherosclerosis, vol. 234, no. 2, pp. 421–425, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Mashitani, Y. Hayashino, S. Okamura, S. Tsujii, and H. Ishii, “Correlations between serum bilirubin levels and diabetic nephropathy progression among japanese type 2 diabetic patients: a prospective cohort study (diabetes distress and care registry at tenri [DDCRT 5]),” Diabetes Care, vol. 37, no. 1, pp. 252–258, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Kawamoto, D. Ninomiya, Y. Hasegawa et al., “Association between serum bilirubin and estimated glomerular filtration rate among elderly persons,” PLoS ONE, vol. 9, no. 12, Article ID e115294, 2014. View at Publisher · View at Google Scholar
  11. K. Toya, T. Babazono, K. Hanai, and Y. Uchigata, “Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus,” Journal of Diabetes Investigation, vol. 5, no. 2, pp. 228–235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Targher, G. Zoppini, G. Cesare Guidi, and G. Lippi, “Relationship between serum bilirubin and kidney function in non-diabetic and diabetic individuals,” Kidney International, vol. 75, no. 8, p. 863, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  14. M. Horio, E. Imai, Y. Yasuda, T. Watanabe, and S. Matsuo, “Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates,” American Journal of Kidney Diseases, vol. 56, no. 1, pp. 32–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Inoguchi, S. Sasaki, K. Kobayashi, R. Takayanagi, and T. Yamada, “Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes,” Journal of the American Medical Association, vol. 298, no. 12, pp. 1398–1400, 2007. View at Google Scholar · View at Scopus
  16. G. Marilena, “New physiological importance of two classic residual products: carbon monoxide and bilirubin,” Biochemical and Molecular Medicine, vol. 61, no. 2, pp. 136–142, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Stocker, Y. Yamamoto, A. F. McDonagh, A. N. Glazer, and B. N. Ames, “Bilirubin is an antioxidant of possible physiological importance,” Science, vol. 235, no. 4792, pp. 1043–1046, 1987. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nishikawa, D. Edelstein, X. L. Du et al., “Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage,” Nature, vol. 404, no. 6779, pp. 787–790, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Fujii, T. Inoguchi, S. Sasaki et al., “Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD(P)H oxidase,” Kidney International, vol. 78, no. 9, pp. 905–919, 2010. View at Publisher · View at Google Scholar · View at Scopus